Lv3
256 积分 2022-07-26 加入
Inhibition of Kit expression by IL-4 and IL-10 in murine mast cells: role of STAT6 and phosphatidylinositol 3'-kinase
5天前
已完结
Molecular craftsmanship: reforging peptide backbones for enhanced drug design
7天前
已完结
Oral Delivery of Peptides and Proteins: Pharmacokinetic Boundaries, Negative Selection, and Route Triage
7天前
已关闭
Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review
7天前
已完结
Response to Papp et al, “Efficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term phase 2 study in patients who participated in the phase 2 STRIDE study”
10天前
已关闭
Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial
10天前
已完结
Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
10天前
已完结
TYK2 as a novel therapeutic target in psoriasis
10天前
已完结
Is the Future Oral? Towards Sustainable and Patient-Centered Biologic Treatment in Dermatology
1个月前
已完结
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites
1个月前
已完结
皖公网安备34019202002308
